<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796818</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0004</org_study_id>
    <secondary_id>NCI-2020-07466</secondary_id>
    <secondary_id>2020-0004</secondary_id>
    <nct_id>NCT04796818</nct_id>
  </id_info>
  <brief_title>An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response</brief_title>
  <official_title>Evaluation of Treatment Response of Colorectal Cancer Liver Metastases With Intravoxel Incoherent Motion Diffusion Weighted Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the treatment response of colorectal cancer that has spread to the liver&#xD;
      (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI).&#xD;
      IVIM DWI is new kind of imaging scan that may help measure changes in disease before and&#xD;
      after chemotherapy in patients with colorectal liver metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether intravoxel incoherent motion (IVIM) diffusion weighted imaging (DWI)&#xD;
      can detect a difference between the changes in the diffusion related parameters in patients&#xD;
      before and after chemotherapy between responders and nonresponders.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Use respiratory-triggered DWI and quantitative T2 maps for the evaluation of colorectal&#xD;
      liver metastases (CLM) after treatment.&#xD;
&#xD;
      II. Assess whether changes in these parameters correlate to pathologic treatment response&#xD;
      (percent necrosis) determined on pathology.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of&#xD;
      starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in the true diffusion coefficient (D)</measure>
    <time_frame>Up to 3 months or 5 months (each cycle is 28 days)</time_frame>
    <description>The absolute changes of parameter D between response and nonresponse groups will be compared using a two-sample t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging</measure>
    <time_frame>Up to 3 months or 5 months (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metastatic Colorectal Carcinoma</condition>
  <condition>Metastatic Malignant Neoplasm in the Liver</condition>
  <condition>Resectable Colorectal Carcinoma</condition>
  <condition>Stage IV Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (IVIM DWI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion Weighted Imaging</intervention_name>
    <description>Undergo IVIM DWI</description>
    <arm_group_label>Diagnostic (IVIM DWI)</arm_group_label>
    <other_name>Diffusion Weighted MRI</other_name>
    <other_name>Diffusion-Weighted Magnetic Resonance Imaging</other_name>
    <other_name>Diffusion-Weighted MR Imaging</other_name>
    <other_name>Diffusion-Weighted MRI</other_name>
    <other_name>DW-MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>DWI MRI</other_name>
    <other_name>DWI-MRI</other_name>
    <other_name>MR Diffusion-Weighted Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with treatment-naive resectable CLM, who will start chemotherapy with&#xD;
             oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with&#xD;
             5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin,&#xD;
             oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent&#xD;
&#xD;
          -  Patients with at least 1 colorectal liver metastasis measuring at least 1 cm&#xD;
&#xD;
          -  Patients with anticipated follow-up before and after surgery at MD Anderson&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have already received preoperative chemotherapy for the CLM or will&#xD;
             undergo radiation therapy, ablative therapies, or other non-surgical therapies&#xD;
             directed at the liver&#xD;
&#xD;
          -  Patients allergic to gadolinium&#xD;
&#xD;
          -  Patients with pacemakers&#xD;
&#xD;
          -  Greater than 400 pounds in weight&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya R Bhosale</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priya R Bhosale</last_name>
    <phone>713-792-0221</phone>
    <email>priya.bhosale@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya R. Bhosale</last_name>
      <phone>713-792-0221</phone>
    </contact>
    <investigator>
      <last_name>Priya R. Bhosale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

